---
title: A CEBPB/IL-1beta/TNF-alpha Feedback Loop Drives Drug Resistance to Venetoclax
  and MDM2 Inhibitors in Monocytic Leukemia
date: '2025-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/40009487/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250227170933&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: MDM2 inhibitors are promising therapeutics for acute myeloid leukemia
  (AML) with wild-type TP53. Through an integrated analysis of functional genomic
  data from primary patient samples, we found that an MDM2 inhibitor idasanutlin,
  like venetoclax, is ineffective against monocytic leukemia (FAB M4/M5). To dissect
  the underlying resistance mechanisms, we explored both intrinsic and extrinsic factors.
  We found that monocytic leukemia cells express elevated levels of CEBPB, which promotes
  ...
disable_comments: true
---
MDM2 inhibitors are promising therapeutics for acute myeloid leukemia (AML) with wild-type TP53. Through an integrated analysis of functional genomic data from primary patient samples, we found that an MDM2 inhibitor idasanutlin, like venetoclax, is ineffective against monocytic leukemia (FAB M4/M5). To dissect the underlying resistance mechanisms, we explored both intrinsic and extrinsic factors. We found that monocytic leukemia cells express elevated levels of CEBPB, which promotes ...